Last mentioned: Mar 24, 2026
Earnings Release
Official announcement of Q4 and FY2025 results and introduction of 2026 guidance.
Guidance Period Start
Commencement of the 2026 fiscal year covered by the new revenue outlook.
Fiscal Year End
Spectral AI closes the year with $15.4M in cash and $19.7M in R&D revenue.
Spectral AI reported full-year 2025 R&D revenue of $19.7 million, driven by its DeepView AI-driven wound diagnostic platform. The company ended the year with $15.4 million in cash and provided its first revenue outlook for 2026, signaling a transition toward commercial scale.
This page surfaces every story mentioning Spectral AI, Inc. across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Spectral AI, Inc. was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |